Biotech Business - September 29, 2020
Galecto raises $64 million to accelerate development of clinical pipeline
Galecto has announced the completion of a $64 million equity financing. This reinforces Galecto’s existing cash balance extending the company’s cash runway into late 2022, it states. Advance its clinical development Galecto intends to use the funds to prepare for a potential conditional approval of GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in the […]
Clinical Trials - September 17, 2020
Galecto’s oral galectin-3 Inhibitor well tolerated in Phase 1
Galecto’s oral small molecule galectin-3 inhibitor, GB1211, was well tolerated in pre-clinical and Phase 1 studies and is ready to start a Phase 2a clinical study to treat liver fibrosis in Non-Alcoholic SteatoHepatitis (NASH). GB1211 has been shown to be effective in several pre-clinical fibrosis models, without any signs of toxicity. Galectin-3 plays a key […]
Pharma Business - September 1, 2020
Galecto receives US and EU orphan drug designation
Galecto has received Orphan Drug Designation (ODD) from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for GB0139 in the treatment of Idiopathic Pulmonary Fibrosis (IPF). The EMA cited clinically relevant biomarker data in IPF patients as a justification for the ODD designation, which provides financial incentives to encourage […]
